United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

A panel advising the CDC poured over new data on vaccines this week before recommending boosters for adults aged 65+, but against shots for workers.

CDC advisors voted in favor of Pfizer boosters for older Americans - but against extra shots for healthcare workers, in a major break with the FDA

Pfizer recipients 65 and older and those living in long-term care facilities would be eligible for a booster. People ages 18 to 64 with an underlying health condition would be eligible too.

CDC panel recommends Pfizer booster for some people

A key CDC advisory group voted to recommend distributing Pfizer and BioNTech's Covid-19 booster shots to older Americans and other vulnerable people.

CDC panel endorses Pfizer Covid booster shots for people 65 and older

FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.

Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People

The European Medicines Agency (EMA) expects to decide on the authorization for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 booster shot at the beginning of October, Reuters reported citing a source directly familiar with the matter. The European decision will follow the FDA authorization granted for the additional dose of the vaccine for certain populations.

EMA To Decide On Pfizer/BioNTech COVID-19 Booster Next Month: Reuters

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 2, 2021. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2021 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Info

Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent fourth-quarter 2021 dividend on the company's common stock, payable December 6, 2021, to holders of the Common Stock of record at the close of business on November 5, 2021. The fourth-quarter 2021 cash dividend will be the 332nd consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources

Pfizer Declares Fourth-Quarter 2021 Dividend

The U.S. Food and Drug Administration on Wednesday authorized a booster dose of the Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine for people aged 65 years and older as well as other high-risk Americans. What Happened: The FDA said that the booster dose can be administered to individuals that meet these criteria six months after completion of their first two doses.

Pfizer COVID-19 Vaccine Booster Shot Approved By FDA For High-Risk Individuals, People 65 And Up

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high ris

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster

Authorization comes a week after an FDA panel recommended against everyone already vaccinated getting the booster.

FDA approves Pfizer booster shots for those over 65 and at-risk adults

The U.S. has moved a step closer to offering booster doses of Pfizer's PFE, +0.07% COVID-19 vaccine to seniors and others at high risk from the virus.

FDA approves Pfizer COVID-19 boosters for seniors, those at high risk

The FDA greenlit a third dose of Pfizer's coronavirus vaccine for seniors, people with underlying health conditions and people with “occupational exposure” to the coronavirus.

FDA Authorizes Pfizer Covid Booster Shots For Seniors And High-Risk Patients — But Not For All Americans

The hope is that booster shots will help protect those most at risk as the pandemic continues to rage.

FDA authorizes boosters of the Pfizer-BioNTech coronavirus vaccine for older adults and others at high risk from COVID-19

The CDC's vaccine advisory committee plans to meet this week, and the agency's panel of experts is expected to vote on plans to distribute third shots.

FDA authorizes Pfizer's Covid booster shots for people 65 and older and other vulnerable Americans

Moderna

It's likely that millions of COVID-19 booster shots will be administered in the U.S. in the coming months, but that doesn't mean companies like Moderna Inc. and Pfizer Inc. will report an unexpected revenue windfall this year.

Whether the FDA approves a COVID-19 booster shot or not, Pfizer and Moderna have already made their money

Pfizer surged, and then slumped, on developments with its Covid-19 vaccine. However, traders are overlooking the broader value in PFE stock.

Despite Vaccine Uncertainty, Pfizer Is a Buy

Endo International plc's (NASDAQ:ENDP) operating company, Par Pharmaceutical Inc, has begun shipping the generic version of Pfizer Inc's (NYSE:PFE) Chantix (varenicline), 0.5 mg and 1 mg tablets. Chantix is a prescription medicine to help adults stop smoking.

Endo Launches Generic Version Of Pfizer's Smoking Cessation Pill

Merck

Nektar Therapeutics

Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.

Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255

Abbott Labs

American Well Corporation

CVS Health

Ginkgo Bioworks Holdings

Talkspace

Welltower

Thanks to the coronavirus pandemic, many people are rethinking the medical sector, boding well for healthcare stocks. The post 7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink appeared first on InvestorPlace.

7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink

A committee that advises the Centers for Disease Control and Prevention begins a two-day meeting that likely will end with detailed recommendations on how the U.S. should roll out booster doses of Pfizer's vaccine.

CDC Committee to Consider Pfizer Booster Today. What to Know.

The deal doubles the country's existing commitment and brings the total number of doses it says it will share to 1 billion.

U.S. To Donate 500 Million More Pfizer Vaccine Doses To Poorer Countries

CDC Committee to Consider Pfizer Booster Today. Here's What to Know.

A Centers for Disease Control and Prevention committee is set to meet Wednesday and Thursday to again discuss the science and possible administration plan for BioNTech SE BNTX, +0.69% and Pfizer Inc.'s PFE, -0.63% COVID-19 booster shot. The CDC's Advisory Committee on Immunization Practices sets out the guidelines for how vaccines should be used in the U.S. The Food and Drug Administration has not approved or authorized an extra dose of the BioNTech and Pfizer vaccine except in people who are immuno-compromised, and an influential FDA committee last week recommended that boosters be limited to older people and those who are at higher risk of severe disease.

CDC committee to meet today and Thursday to again discuss BioNTech and Pfizer's COVID-19 booster

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) will provide the U.S. government additional 500 million doses of its COVID-19 vaccine. The doses at a not-for-profit price will be used for donations to low- and lower-middle-income countries and the organizations that support them.

US To Donate Additional 500M Pfizer-BioNTech COVID-19 Vaccine Doses To Lower Income Nations

Pfizer Inc. PFE, -0.63% and BioNTech SE BNTX, +0.69% announced Wednesday plans to provide an additional 500 million doses of their COVID-19 vaccine to the U.S. government. The additional doses will be sold at "not-for-profit" prices, for donation to low- and lower-middle-income countries, as defined by Gavi's COVAX Advanced Market Commitment (AMC) and the 55 member states of the African Union.

News for Pfizer Stock (PFE)